Whittier Trust Co. Acquires 229 Shares of Intuitive Surgical, Inc. (NASDAQ:ISRG)

Whittier Trust Co. raised its holdings in Intuitive Surgical, Inc. (NASDAQ:ISRG) by 2.6% in the 1st quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 9,166 shares of the medical equipment provider’s stock after purchasing an additional 229 shares during the quarter. Whittier Trust Co.’s holdings in Intuitive Surgical were worth $3,658,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently bought and sold shares of the business. Provence Wealth Management Group acquired a new stake in shares of Intuitive Surgical in the 4th quarter valued at $276,000. Portside Wealth Group LLC lifted its position in Intuitive Surgical by 8.2% during the 4th quarter. Portside Wealth Group LLC now owns 816 shares of the medical equipment provider’s stock valued at $275,000 after purchasing an additional 62 shares during the period. Sequoia Financial Advisors LLC boosted its stake in shares of Intuitive Surgical by 58.0% in the 4th quarter. Sequoia Financial Advisors LLC now owns 8,315 shares of the medical equipment provider’s stock valued at $2,805,000 after purchasing an additional 3,054 shares during the last quarter. Public Employees Retirement System of Ohio grew its position in shares of Intuitive Surgical by 5.4% during the 4th quarter. Public Employees Retirement System of Ohio now owns 191,283 shares of the medical equipment provider’s stock worth $64,531,000 after buying an additional 9,869 shares during the period. Finally, HCR Wealth Advisors raised its stake in shares of Intuitive Surgical by 26.3% during the fourth quarter. HCR Wealth Advisors now owns 1,042 shares of the medical equipment provider’s stock worth $352,000 after buying an additional 217 shares during the last quarter. Institutional investors and hedge funds own 83.64% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages have issued reports on ISRG. Evercore ISI raised their price objective on shares of Intuitive Surgical from $385.00 to $425.00 and gave the company an “in-line” rating in a research note on Tuesday, July 2nd. Robert W. Baird reduced their target price on Intuitive Surgical from $440.00 to $436.00 and set an “outperform” rating on the stock in a report on Friday, April 19th. BTIG Research boosted their target price on Intuitive Surgical from $412.00 to $421.00 and gave the stock a “buy” rating in a research report on Friday, April 19th. Jefferies Financial Group increased their price target on shares of Intuitive Surgical from $365.00 to $375.00 and gave the company a “hold” rating in a research report on Friday, April 19th. Finally, The Goldman Sachs Group started coverage on shares of Intuitive Surgical in a report on Thursday, May 30th. They set a “buy” rating and a $500.00 price objective for the company. Six investment analysts have rated the stock with a hold rating and fourteen have given a buy rating to the stock. According to MarketBeat.com, Intuitive Surgical presently has an average rating of “Moderate Buy” and an average target price of $407.68.

Insider Transactions at Intuitive Surgical

In other Intuitive Surgical news, SVP Mark Brosius sold 175 shares of the company’s stock in a transaction on Monday, May 13th. The shares were sold at an average price of $389.16, for a total transaction of $68,103.00. Following the sale, the senior vice president now directly owns 883 shares of the company’s stock, valued at $343,628.28. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other Intuitive Surgical news, SVP Mark Brosius sold 175 shares of the business’s stock in a transaction that occurred on Monday, May 13th. The stock was sold at an average price of $389.16, for a total transaction of $68,103.00. Following the transaction, the senior vice president now owns 883 shares of the company’s stock, valued at $343,628.28. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, EVP Robert Desantis sold 1,498 shares of the firm’s stock in a transaction that occurred on Friday, April 26th. The shares were sold at an average price of $369.92, for a total value of $554,140.16. Following the completion of the sale, the executive vice president now directly owns 5,507 shares of the company’s stock, valued at $2,037,149.44. The disclosure for this sale can be found here. Insiders have sold a total of 17,956 shares of company stock worth $6,927,011 in the last 90 days. Corporate insiders own 0.80% of the company’s stock.

Intuitive Surgical Stock Down 0.5 %

ISRG traded down $2.23 during trading hours on Tuesday, hitting $442.30. 886,435 shares of the company’s stock were exchanged, compared to its average volume of 1,509,367. Intuitive Surgical, Inc. has a 1-year low of $254.85 and a 1-year high of $448.10. The stock’s 50-day moving average is $411.61 and its two-hundred day moving average is $388.14. The stock has a market cap of $156.88 billion, a price-to-earnings ratio of 80.24, a PEG ratio of 5.73 and a beta of 1.39.

Intuitive Surgical (NASDAQ:ISRG) last announced its quarterly earnings data on Thursday, April 18th. The medical equipment provider reported $1.50 earnings per share for the quarter, beating the consensus estimate of $1.40 by $0.10. Intuitive Surgical had a return on equity of 12.91% and a net margin of 27.16%. The company had revenue of $1.89 billion during the quarter, compared to analysts’ expectations of $1.87 billion. During the same quarter last year, the company earned $1.00 EPS. Intuitive Surgical’s revenue for the quarter was up 11.5% compared to the same quarter last year. On average, equities research analysts anticipate that Intuitive Surgical, Inc. will post 4.8 EPS for the current year.

Intuitive Surgical Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.